Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01925157 | A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA) | PHASE1 | COMPLETED | 43 | — | — | Aug 1, 2013 | Sep 1, 2015 | Oct 1, 2015 | 4 | Bulgaria, Moldova +2 |
| Arm | Type | Description |
|---|---|---|
| LY3090106 (Healthy) | EXPERIMENTAL | Healthy participants will receive a single dose of LY3090106 in dose escalation cohorts subcutaneously (SQ). |
| Placebo (Healthy) | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo matching LY3090106 SQ. |
| LY3090106 (RA) | EXPERIMENTAL | Participants with RA will receive a single dose of LY3090106 in dose escalation cohorts SQ or intravenously (IV). |
| Placebo (RA) | PLACEBO_COMPARATOR | Participants with RA will receive a single dose of placebo matching LY3090106 SQ. |
| Name | Type | Description |
|---|---|---|
| LY3090106 - SQ | BIOLOGICAL | Administered SQ. |
| LY3090106 - IV | BIOLOGICAL | Administered IV. |
| Placebo - SQ | BIOLOGICAL | Administered SQ. |
Inclusion Criteria for Healthy Participants: * Males or non-pregnant females age 18 to 65 years * Body Mass Index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m\^2) Inclusion Criteria for Participants for RA: * Diagnosis of at least mildly active adult-onset RA * Positive anti-citrullina...